Cargando…

Deciphering the Precise Target for Saroglitazar Associated Antiangiogenic Effect: A Computational Synergistic Approach

[Image: see text] Antidiabetic drugs that have a secondary pharmacological effect on angiogenesis inhibition may help diabetic patients delay or avoid comorbidities caused by angiogenesis including malignancies. In recent studies, saroglitazar has exhibited antiangiogenic effects in diabetic retinop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dabral, Swarna, Khan, Imran Ahmd, Pant, Tarun, Khan, Sabina, Prakash, Prem, Parvez, Suhel, Saha, Nilanjan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157850/ https://www.ncbi.nlm.nih.gov/pubmed/37151537 http://dx.doi.org/10.1021/acsomega.2c07570

Ejemplares similares

Saroglitazar – A Potential Therapeutic Option in Treating NASH? [Letter]
por: Shuja, Syed Hasan, et al.
Publicado: (2021)

Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence
por: Sosale, Aravind, et al.
Publicado: (2015)

Observational Study of Effects of Saroglitazar on Glycaemic and Lipid Parameters on Indian Patients with Type 2 Diabetes
por: Chatterjee, Sanjay, et al.
Publicado: (2015)

Significant Reduction of Elevated Triglycerides and Liver Fibrosis in Diabetic Dyslipidemia with Saroglitazar: A Case Report
por: Roy, Sayak, et al.
Publicado: (2019)

Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial
por: Rodriguez-Gutierrez, Rene, et al.
Publicado: (2022)

Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies
por: Chhabra, Manik, et al.
Publicado: (2022)

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
por: Jain, Mukul R., et al.
Publicado: (2017)

Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis
por: Akbari, Rasoul, et al.
Publicado: (2021)

A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis
por: Vuppalanchi, Raj, et al.
Publicado: (2021)

Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study
por: Goyal, Omesh, et al.
Publicado: (2020)

Role of Melatonin in Traumatic Brain Injury and Spinal Cord Injury
por: Naseem, Mehar, et al.
Publicado: (2014)

COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials
por: Chakraborty, Rohan, et al.
Publicado: (2020)

Antiangiogenic therapy
por: Avitabile, T
Publicado: (2010)

Saroglitazar in Non-alcoholic Fatty Liver Disease From Bench to Bedside: A Comprehensive Review and Sub-group Meta-Analysis
por: Roy, Akash, et al.
Publicado: (2023)

Deciphering the Immunomodulatory Role of Cyclin-Dependent Kinase 4/6 Inhibitors in the Tumor Microenvironment
por: Pandey, Pratibha, et al.
Publicado: (2023)

Neuroprotective Effects of Natural Antioxidants Against Branched-Chain Fatty Acid-Induced Oxidative Stress in Cerebral Cortex and Cerebellum Regions of the Rat Brain
por: Chaudhary, Shaista, et al.
Publicado: (2022)

A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy
por: Deshpande, Alka, et al.
Publicado: (2016)

Effect of an Integrated Physiotherapy Protocol on Knee Osteoarthritis Patients: A Preliminary Study
por: Khan, Sohrab Ahmad, et al.
Publicado: (2023)

The inefficacy of antiangiogenic therapies
por: Ribatti, Domenico
Publicado: (2010)

Antiangiogenic Therapy for Glioma
por: Cea, Valentina, et al.
Publicado: (2012)

Antiangiogenic Cancer Therapy
por: Maxwell, P H, et al.
Publicado: (2009)

Antiangiogenic effects of oridonin
por: Tian, Lili, et al.
Publicado: (2017)

Antiangiogenic Effect of Alkaloids
por: Alasvand, Masoud, et al.
Publicado: (2019)

Antiangiogeneic Strategies in Mesothelioma
por: Nowak, Anna K., et al.
Publicado: (2020)

Genomic analyses of aminoacyl tRNA synthetases from human-infecting helminths
por: Goel, Preeti, et al.
Publicado: (2019)

Nrf2/HO-1 mediates the neuroprotective effects of pramipexole by attenuating oxidative damage and mitochondrial perturbation after traumatic brain injury in rats
por: Salman, Mohd., et al.
Publicado: (2020)

Behavioral Tagging: Role of Neurotransmitter Receptor Systems in Novel Object Recognition Long-Term Memory
por: Vishnoi, Shruti, et al.
Publicado: (2022)

Mitochondria-Related Apoptosis Regulation by Minocycline: A Study on a Transgenic Drosophila Model of Alzheimer’s Disease
por: Khatoon, Rehana, et al.
Publicado: (2022)

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
por: Kumar, Divya P., et al.
Publicado: (2020)

Saroglitazar ameliorates monosodium glutamate-induced obesity and associated inflammation in Wistar rats: Plausible role of NLRP3 inflammasome and NF- κB
por: Nabi, Sayima, et al.
Publicado: (2022)

Vitamin E Loaded Naringenin Nanoemulsion via Intranasal Delivery for the Management of Oxidative Stress in a 6-OHDA Parkinson's Disease Model
por: Gaba, Bharti, et al.
Publicado: (2019)

Melatonin and Ischemic Stroke: Mechanistic Roles and Action
por: Andrabi, Syed Suhail, et al.
Publicado: (2015)

Role of some epigenetic factors in DNA damage response pathway
por: Tiwari, Mrinalini, et al.
Publicado: (2017)

Progesterone induces neuroprotection following reperfusion-promoted mitochondrial dysfunction after focal cerebral ischemia in rats
por: Andrabi, Syed Suhail, et al.
Publicado: (2017)

Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment
por: Xue, Liting, et al.
Publicado: (2021)

Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects
por: Jani, Rajendra H., et al.
Publicado: (2013)

Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models
por: Jain, Mukul R, et al.
Publicado: (2015)

An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Mitra, Asis
Publicado: (2020)

Clinical Case Series of Decrease in Shear Wave Elastography Values in Ten Diabetic Dyslipidemia Patients Having NAFLD with Saroglitazar 4 mg: An Indian Experience
por: Roy, Sayak
Publicado: (2020)

Neuromodulatory Effects of Hesperidin in Mitigating Oxidative Stress in Streptozotocin Induced Diabetes
por: Ashafaq, Mohammad, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_909393ie4mttmeetfsaadiakb8